Palisade Bio, Inc. (PALI)
1.24
+0.12
(+10.71%)
USD |
NASDAQ |
Nov 03, 16:00
1.24
0.00 (0.00%)
After-Hours: 18:09
Palisade Bio Net Income (Quarterly) : -10.57M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -10.57M |
| March 31, 2026 | -9.60M |
| December 31, 2025 | -8.899M |
| September 30, 2025 | -2.868M |
| June 30, 2025 | -2.784M |
| March 31, 2025 | -2.23M |
| December 31, 2024 | -3.344M |
| September 30, 2024 | -3.487M |
| June 30, 2024 | -4.08M |
| March 31, 2024 | -3.527M |
| December 31, 2023 | -2.971M |
| September 30, 2023 | -3.612M |
| June 30, 2023 | -3.393M |
| March 31, 2023 | -2.34M |
| December 31, 2022 | -4.008M |
| September 30, 2022 | -3.991M |
| June 30, 2022 | -2.344M |
| March 31, 2022 | -4.205M |
| December 31, 2021 | 1.073M |
| September 30, 2021 | 5.118M |
| June 30, 2021 | -31.75M |
| March 31, 2021 | -4.03M |
| December 31, 2020 | -4.244M |
| September 30, 2020 | -1.843M |
| June 30, 2020 | -1.851M |
| Date | Value |
|---|---|
| March 31, 2020 | -7.575M |
| December 31, 2019 | -2.038M |
| September 30, 2019 | -1.763M |
| June 30, 2019 | -1.437M |
| March 31, 2019 | -3.114M |
| December 31, 2018 | -0.3203M |
| September 30, 2018 | -1.830M |
| June 30, 2018 | -0.627M |
| March 31, 2018 | -2.147M |
| December 31, 2017 | -3.316M |
| September 30, 2017 | -0.1338M |
| June 30, 2017 | -4.649M |
| March 31, 2017 | -7.567M |
| December 31, 2016 | -5.396M |
| September 30, 2016 | -5.220M |
| June 30, 2016 | -3.852M |
| March 31, 2016 | -6.606M |
| December 31, 2015 | -4.765M |
| September 30, 2015 | -5.638M |
| June 30, 2015 | -5.448M |
| March 31, 2015 | -5.053M |
| December 31, 2014 | -5.503M |
| September 30, 2014 | -4.455M |
| June 30, 2014 | -6.751M |
| March 31, 2014 | -5.919M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.50M |
| Total Expenses (Quarterly) | 11.07M |
| EPS Diluted (Quarterly) | -0.05 |
| Enterprise Value | 69.26M |
| Profit Margin (Quarterly) | -2.11K% |
| Earnings Yield | -43.17% |
| Normalized Earnings Yield | -45.70 |